Comparison of the Efficacy of Prolotherapy Injection Therapy & Local Anesthetic Injection Therapy.

NCT ID: NCT05239091

Last Updated: 2023-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-01

Study Completion Date

2022-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Myofascial pain syndrome is a disease characterized by pain over the trigger point in a taut muscle band. After the correct diagnosis is made, many treatment methods can be applied.

One of these treatments is the treatment with prolotherapy injection. Proliferant reveals defense mechanisms remove them and then start the healing process in the damaged area. Usually, dextrose water is used. Lidocaine is an anesthetic. With lidocaine injection, the passage of painful stimuli is prevented and the opioid system is activated. The aim of the study is to compare the efficacy of prolotherapy and lidocaine treatment in the myofascial pain syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective randomized controlled study. The population of the study consists of volunteer patients who can apply to Istanbul Physical Therapy and Rehabilitation Training and Research Hospital, and meet the inclusion criteria. Twenty-eight people will be selected from the participants who volunteered for the study and will be divided into the study group and control groups with the permutation block randomization method. At the beginning, all patients will be asked about their gender, age, body mass index, education level, occupation, duration of complaint, previous treatments, and the last time received treatment.

Patients will be recruited equally to the control and study groups, with 14 patients in each group. 15% dextrose injection treatment will be applied to the study group. 2% lidocaine injection treatment will be applied to the control group. The subjects will be asked to sit on a chair and the trigger point will be determined in the upper trapezius muscle in both groups. A total of 3 sessions of injection treatment will be applied to the trigger points (at the beginning, at the 2nd, and 4th weeks). It will be planned to be 2 weeks between each injection session. 1 month after the third session injection, patients will be called for control purposes.

The application will be made using a 25 gauge injector. Before the injection, the skin will be cleaned with alcohol and then dried. All patients will be injected into the trigger points in the upper trapezius muscle. Trigger point injection, on the other hand, is the compression of the isolated skin with the help of the thumb and middle finger and advancing the needle into the muscle at a 90-degree angle. Before the injection, a puncture will be made to make sure the needle is not in the blood vessel. Some of the mixtures will be injected into the trigger point and the rest around the trigger point. The same injection technique will be applied in both the control and study groups. Measurements will be made at the beginning (week 0), week 2, and week 4 before and after the injection when they come to the 1-month control. Adverse events related to injections will be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myofascial Pain Syndrome of Neck

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Lidocaine dextrose prolotherapy pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, randomized, triple blinded, clinical trials
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Patients, Outcomes Assessor, and Investigator (statistician) will be blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dextrose prolotherapy

:%15 dextrose prolotherapy injection will be applied to trigger point

Group Type EXPERIMENTAL

Dextrose solution

Intervention Type DRUG

A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.

Lidocaine

%2 lidocaine injection will be applied to trigger point

Group Type ACTIVE_COMPARATOR

Lidocain

Intervention Type DRUG

A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dextrose solution

A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.

Intervention Type DRUG

Lidocain

A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dextrose prolotherapy Local anesthetic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary myofascial pain syndrome (MAS) in the upper trapezius muscle
* At least one active myofascial trigger point in the upper trapezius muscle
* Patients with symptoms between 1 day and 2 months
* Age:18 to 65 years old
* Cases who did not receive any physical therapy or medication to relieve pain

Exclusion Criteria

* Having a sensory defect in the area to be injected
* Active inflammatory, rheumatic, or infectious disease
* Peripheral nerve lesions such as polyneuropathy, radiculopathy
* Those who use anticoagulants, those with bleeding diathesis
* Patients whose skin surface is not intact in the area to be injected
* Patients diagnosed with fibromyalgia or other common musculoskeletal pain syndromes
* Patients with a history of panic attacks
* Those who are allergic to local anesthetic drug
* People showing symptoms of Covid-19
* Those who have had a trigger point injection in the last 6 months
* Those who are pregnant
* Those who have undergone vertebral or shoulder surgery in the last 1 year
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Necat Akgun

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fatmanur Kesiktaş, Prof

Role: STUDY_DIRECTOR

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istanbul Physical Medicine Rehabilitation Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FTRinjection

Identifier Type: -

Identifier Source: org_study_id